| Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update |
Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial |
globenewswire.com |
2025-05-08 11:00:00 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics Announces New Employment Inducement Grants |
FREDERICK, Md., May 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On May 1, 2025, the Company issued to these employees options to purchase an aggregate of 27,700 shares of the Company's common stock with an exercise price of $12.27, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on May 1, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on May 1, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company. |
globenewswire.com |
2025-05-02 11:05:00 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial |
After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 |
globenewswire.com |
2025-04-08 11:00:00 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics Announces New Employment Inducement Grants |
FREDERICK, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On April 1, 2025, the Company issued to these employees options to purchase an aggregate of 31,000 shares of the Company's common stock with an exercise price of $12.49, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on April 1, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on April 1, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company. |
globenewswire.com |
2025-04-02 11:05:00 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference |
FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 2:15 p.m. ET. |
globenewswire.com |
2025-04-01 11:00:00 |
Czytaj oryginał (ang.) |
| Substantial Insider Buying: American Express, Asana, and More |
Retirement can be daunting, but it doesn't need to be. Imagine having an expert in your corner to help you with your financial goals. |
247wallst.com |
2025-03-30 15:16:56 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics Announces New Employment Inducement Grant |
FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to one new employee. On March 3, 2025, the Company issued to this employee an option to purchase 2,650 shares of the Company's common stock with an exercise price of $17.50, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company's board of directors. The option vests as to 25% on March 3, 2026, and then in three equal annual installments thereafter such that the option will be fully vested on March 3, 2029. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee's entry into employment with the Company. |
globenewswire.com |
2025-03-06 09:05:00 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics to Participate in Upcoming Investor Conferences |
FREDERICK, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in February and March: |
globenewswire.com |
2025-02-18 09:00:00 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics Announces New Employment Inducement Grants |
FREDERICK, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On February 3, 2025, the Company issued to these employees options to purchase an aggregate of 168,360 shares of the Company's common stock with an exercise price of $19.89, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The option vests as to 25% on February 3, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on February 3, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company. |
globenewswire.com |
2025-02-06 09:05:00 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis |
FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process on the overall design of the Company's planned Phase 3 AURORA trial for Descartes-08, its lead mRNA cell therapy candidate, in myasthenia gravis (MG). |
globenewswire.com |
2025-01-27 09:00:00 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics Announces New Employment Inducement Grants |
FREDERICK, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to three new employees. On January 2, 2025, the Company issued to these employees options to purchase an aggregate of 19,324 shares of the Company's common stock with an exercise price of $16.93, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The option vests as to 25% on January 2, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on January 2, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company. |
globenewswire.com |
2025-01-07 09:05:00 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics Announces New Employment Inducement Grants |
FREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On December 12, 2024, the Company issued to these employees options to purchase an aggregate of 25,602 shares of the Company's common stock with an exercise price of $20.12, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The option vests as to 25% on December 12, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on December 12, 2028. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company. |
globenewswire.com |
2024-12-18 09:05:00 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial |
Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of ≥3 points at Month 4 relative to placebo |
globenewswire.com |
2024-12-03 08:00:00 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit |
Company to host conference call and webcast with key opinion leader on December 3, 2024, at 7:30 a.m. ET Company to host conference call and webcast with key opinion leader on December 3, 2024, at 7:30 a.m. ET |
globenewswire.com |
2024-11-21 09:00:00 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics: Uncertainty Remains |
Cartesian Therapeutics' stock has rebounded sharply recently despite no significant news, driven partly by insider buying after a disappointing Phase 2b trial for Descartes-08 in myasthenia gravis. The company leverages its RNA Armory platform for mRNA cell therapies, focusing on autoimmune diseases, with Descartes-08 and Descartes-15 as its main assets. Descartes-08 showed mixed results in Phase 2b for MG, raising concerns due to endpoint changes and trial anomalies, yet plans continue for a pivotal trial in 2025. |
seekingalpha.com |
2024-11-10 14:26:16 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics Announces New Employment Inducement Grants |
FREDERICK, Md., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to two new employees. On November 4, 2024, the Company issued to these employees options to purchase an aggregate of 4,854 shares of the Company's common stock with an exercise price of $19.11, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The option vests as to 25% on November 4, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on November 4, 2028. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company. |
globenewswire.com |
2024-11-08 09:05:00 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates |
Cartesian Therapeutics, Inc. (RNAC) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $2.40 per share a year ago. |
zacks.com |
2024-11-07 11:40:23 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting |
Company continues to expect to hold an End-of-Phase 2 meeting with the FDA by year-end Company continues to expect to hold an End-of-Phase 2 meeting with the FDA by year-end |
globenewswire.com |
2024-10-15 11:00:00 |
Czytaj oryginał (ang.) |
| Insider Buying Slows, but Not for 7 These Buyers |
24/7 Wall St. Insights Insider buying slowed to a trickle ahead of the third-quarter earnings reporting season. |
247wallst.com |
2024-10-13 13:45:27 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last? |
Cartesian Therapeutics, Inc. (RNAC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2024-10-04 14:15:29 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics Announces New Employment Inducement Grants |
GAITHERSBURG, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On October 1, 2024, the Company issued to these employees options to purchase an aggregate of 60,961 shares of the Company's common stock with an exercise price of $17.11, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The option vests as to 25% on October 1, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on October 1, 2028. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company. |
globenewswire.com |
2024-10-04 11:05:00 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results |
Cartesian Therapeutics, Inc.'s Descartes-08 mRNA CAR-T therapy shows promising Phase 2 results for myasthenia gravis without preconditioning chemotherapy. The company's RNA Armory platform enables precise, temporary cell modulation, reducing long-term side effects and avoiding genomic integration. Descartes-08 has received FDA Orphan and RMAT designations, with a Phase 3 trial expected to begin by the end of 2024. |
seekingalpha.com |
2024-09-17 13:45:28 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics Announces New Employment Inducement Grant |
GAITHERSBURG, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to a new employee. On September 3, 2024, the Company issued to this employee an option to purchase 3,864 shares of the Company's common stock with an exercise price of $13.12, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company's board of directors. The option vests as to 25% on September 3, 2025, and then in three equal annual installments thereafter such that the option will be fully vested on September 3, 2028. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee's entry into employment with the Company. |
globenewswire.com |
2024-09-06 11:05:00 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15 |
Descartes-15 observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing in preclinical studies |
globenewswire.com |
2024-09-03 11:00:00 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics, Inc. (RNAC) Q2 Earnings and Revenues Top Estimates |
Cartesian Therapeutics, Inc. (RNAC) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of a loss of $0.81 per share. This compares to loss of $2.10 per share a year ago. |
zacks.com |
2024-08-08 13:35:53 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics Announces New Employment Inducement Grants |
GAITHERSBURG, Md., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to seven new employees. On August 1, 2024, the Company issued to these employees options to purchase an aggregate of 100,457 shares of the Company's common stock with an exercise price of $15.47, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. Each of the options vest as to 25% on August 1, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on August 1, 2028. Each of the options has a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee's entry into employment with the Company. |
globenewswire.com |
2024-08-07 20:05:00 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics Announces New Employment Inducement Grants |
GAITHERSBURG, Md., July 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to new employees. On July 1, 2024, the Company issued to these employees options to purchase an aggregate of 35,198 shares of the Company's common stock with an exercise price of $24.27, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. Each of the options vest as to 25% on July 1, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on July 1, 2028. Each of the options has a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee's entry into employment with the Company. |
globenewswire.com |
2024-07-08 20:05:00 |
Czytaj oryginał (ang.) |
| Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates |
Cartesian (RNAC) announced that the phase IIb study in MG patients has achieved its primary endpoints. However, the stock nosedives following an equity financing announcement. |
zacks.com |
2024-07-03 19:25:39 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik |
Dr. Malik to deepen strategic leadership and provide regulatory and clinical development innovation expertise Dr. Malik to deepen strategic leadership and provide regulatory and clinical development innovation expertise |
globenewswire.com |
2024-07-02 20:05:00 |
Czytaj oryginał (ang.) |
| Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data |
Cartesian Therapeutics, Inc. achieved positive results from the phase 2b study using Descartes-08 for the treatment of patients with myasthenia gravis; the End of phase 2 meeting with the FDA is expected by the end of 2024. The global market for generalized myasthenia gravis is projected to reach $7.5 billion by 2031. A soon-to-be-initiated phase 2 basket study would explore other autoimmune disorder indications for Descartes-08; The global autoimmune disease therapeutics market is expected to reach $123.5 billion by 2033. |
seekingalpha.com |
2024-07-02 16:55:10 |
Czytaj oryginał (ang.) |
| Cartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T Drugs |
Cartesian Therapeutics reported a "watershed moment" for its autoimmune-disease drug on Tuesday, but the biotech stock plunged. |
investors.com |
2024-07-02 14:55:22 |
Czytaj oryginał (ang.) |